Cicada Covid Variant and the quiet return that has health experts watching
At a moment when many Americans have tried to file COVID-19 under “past tense, ” the cicada covid variant has reintroduced a familiar kind of uncertainty: not panic, but vigilance. Officially called BA. 3. 2, it first appeared in 2024, seemed to go dormant, and then resurfaced in the United States late last year—an arc that helped earn it its insect-inspired nickname.
What do we know about the Cicada Covid Variant right now?
The BA. 3. 2 variant was first identified in South Africa in November 2024. It was detected in the United States in one traveler seven months later, in June 2025. After that, it was not spotted in the U. S. again until late December and early January, when more evidence of the variant emerged.
Public health experts track variants through multiple forms of surveillance: testing samples of wastewater, collecting voluntary nasal swabs from travelers, and reviewing viral samples collected from patients by doctors and hospitals. As of Feb. 11 (ET), BA. 3. 2 had been detected in 25 different states, based on U. S. Centers for Disease Control and Prevention data referenced in the available context.
Even with that geographic footprint, one key point remains: BA. 3. 2 is not dominant. “BA. 3. 2 is currently a minority strain, based on the most recent data available from CDC, ” said Dr. Robert H. Hopkins, medical director for the National Foundation for Infectious Diseases.
What are experts watching for, and why does BA. 3. 2 stand out?
The concern around the cicada covid variant is rooted less in what it has done so far in the U. S. —described as only a few cases—and more in what its genetic makeup suggests it could do. BA. 3. 2 is part of the omicron family of variants, but it carries “lots of mutations, ” estimated at 70 to 75 compared with dominant strains. Those changes may help it evade immune defenses provided by the current COVID-19 vaccine.
At the same time, specialists emphasized that the evidence is still developing. Scientists are still studying BA. 3. 2, and much of what is understood about how it behaves comes from laboratory data rather than clinical data.
Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center, said the early data do not suggest greater severity or distinctive clinical presentations. “The early data would indicate that it is not more severe, or it doesn’t have any distinctive clinical presentations, ” Schaffner said. He added this has been typical of COVID-19 variants over the last couple of years, with symptoms not changing much from variant to variant and the disease not becoming significantly more severe overall.
What remains unclear is how BA. 3. 2 will behave in the coming months in the U. S. Laboratory tests suggest it may be less transmissible, Schaffner said, but he also noted the limits of what can be known at this stage: “We don’t know how quickly it will circulate or whether it will outrun the other variants that are out there at the moment, because we don’t know how contagious it is. ”
How widely has BA. 3. 2 spread, and what should people take from the Europe trend?
While the U. S. has seen only a small number of cases so far in the available evidence, BA. 3. 2 gained traction in Europe, prompting experts to watch for similar trends in North America. In Northern Europe, it became more prevalent this winter, with 30% of cases in Germany, Denmark, and The Netherlands linked to the variant.
That contrast—limited U. S. cases alongside notable European prevalence—captures the emotional reality of living with an evolving virus: the data can be calm and still demanding of attention. Public health surveillance, by design, catches signals early and sometimes before the public feels any change in daily life.
So the most honest framing, based strictly on what is known in the provided context, is also the most restrained: BA. 3. 2 has been detected across a wide span of U. S. states and has circulated more strongly in parts of Europe; experts are studying its mutations and monitoring whether it will spread more widely; and there is no evidence yet that it is more severe than prior variants.
Back in that uneasy space between memory and the present tense, the cicada covid variant is a reminder that surveillance never really stops—even when the noise of the pandemic has faded.
